Alerta

一种预防和治疗酒精性肝损伤的中药组合物及其制备方法和应用

Resumen de: CN122912041A

本发明公开了一种预防和治疗酒精性肝损伤的中药组合物及其制备方法和应用，涉及中医药技术领域。制备方法包括：取枳椇子、葛花、五味子、葛根混合，加入水，加入锌盐溶液，煎煮提取，过滤得含有Zn‑黄酮配合物的提取液；向提取液中加入蛋白，用碱调节pH至8.0‑10.0，再用酸调节pH至6.5‑7.5，使形成稳定的纳米颗粒；纯化、干燥即得。本发明通过“高温驱动自组装‑金属离子配位‑pH驱动蛋白包埋”一体化技术，将中药活性成分高效组装为蛋白‑金属‑黄酮三元复合纳米颗粒，显著提高了活性成分的稳定性和生物利用度，在解酒护肝方面表现出协同增效作用。

用于软骨再生的肽及其用途

Resumen de: WO2024122718A1

The present application relates to a peptide having a cartilage regeneration effect and uses thereof, and provides a peptide consisting of an amino acid sequence represented by SEQ ID NO: 1 or Glu (E)-Asp (D)-Asp (D), a composition for cartilage regeneration comprising the peptide, and a pharmaceutical composition for preventing or treating cartilage diseases, comprising the composition for cartilage regeneration as an active ingredient.

一种纳米氧胶囊及其制备方法和应用

Resumen de: CN122911924A

本发明涉及生物医药技术领域，提供一种纳米氧胶囊及其制备方法和应用。所述纳米氧胶囊包括溶解有氧气的全氟化碳内核和包覆所述全氟化碳内核的蛋白外壳。所述纳米氧胶囊作为口服制剂，能够用于非酒精性脂肪性肝病的治疗。该纳米氧胶囊能够直接在缺氧肠道局部缓慢释放氧气，生理性地下调肠道上皮细胞中HIF‑2α的表达水平，最终实现逆转NAFLD进展的治疗目的。同时，该策略因仅在肠道局部发挥作用，不影响全身HIF‑2α的正常生理功能，从而有效规避了全身性抑制剂引起的糖异生异常和血糖升高等代谢副作用。

一种代谢调控-免疫激活协同纳米材料及制备方法和应用

Resumen de: CN122912116A

本发明涉及一种代谢调控‑免疫激活协同纳米材料及制备方法和应用，该制备方法包括以下步骤：金纳米球的制备、介孔聚多巴胺包覆和锰离子配位、介孔聚多巴胺包覆和锰离子配位和细胞膜包覆；本发明通过在纳米材料中引入乳酸氧化酶，在肿瘤局部持续催化乳酸转化，显著降低乳酸水平，从而解除乳酸及其伴随酸性环境对免疫细胞功能的抑制，为后续免疫激活提供必需的代谢前处理条件，本发明针对胰腺导管腺癌高糖酵解、乳酸积累严重和免疫抑制显著的微环境特征进行优化，在肿瘤中具有更明确的适应性和更突出的技术优势。

树突状细胞内高表达5'UTR的鉴定和应用

Resumen de: CN122918058A

本发明涉及树突状细胞内高表达5'UTR的鉴定和应用。具体来说，本发明成功筛选出两条高性能5'UTR序列（UTR39、UTR48），为mRNA疫苗的优化提供了新的候选元件，更重要的是揭示了5'UTR表达强度与免疫刺激阈值之间的调控关系——高性能5'UTR在二次及后续多次免疫过程中，需匹配适宜的低剂量策略，才能在最大化激活CTL抗肿瘤免疫应答的同时，避免过度免疫刺激带来的不利影响。这一发现为mRNA肿瘤疫苗的剂量优化、给药方案设计提供了重要的实验依据和理论支撑，对推动mRNA疫苗在肿瘤免疫治疗领域的规范化应用具有重要的实践意义。

一种负载HKUST-1@PDA的可注射自修复水凝胶及其制备方法和应用

Resumen de: CN122911886A

本发明属于水凝胶制备技术领域，公开了一种负载HKUST‑1@PDA的可注射自修复水凝胶及其制备方法和应用。本发明所述水凝胶包括席夫碱动态交联水凝胶基质以及分散于所述水凝胶基质中的聚多巴胺（PDA）改性HKUST‑1；所述聚多巴胺改性HKUST‑1是以HKUST‑1晶体为内核、表面包覆多巴胺原位自聚合壳层的核壳结构颗粒；所述水凝胶在808 nm近红外光照下触发铜离子突释并产生·OH和·O2‑，无光照下铜离子释放浓度≤1μg/mL。该材料既能通过微创注射原位成胶，又能利用光动力效应与高浓度铜离子协同控制感染，并通过缓释低浓度铜离子促进肌腱干细胞增殖迁移，促进肌腱胶原有序再生，解决感染控制与组织修复难以同步的临床难题。

一种基于铜死亡的具有TME响应的球形纳米材料的制备方法及抗肿瘤应用

Resumen de: CN122911922A

本发明公开了一种基于铜死亡的“三明治”结构的纳米材料的制备方法及其抗肿瘤应用。该纳米材料的制备以羟丙基甲基纤维素、壳聚糖、海藻酸钠为原料，采用伊利司莫与醋酸铜结合形成伊利司莫‑铜（ESCu）被包裹于纳米材料中，制备得到球形纳米材料CHA@ESCu。实验证明ESCu能够特异性结合线粒体中的FDX1，从而将铜离子转运至肿瘤细胞的线粒体中，诱导铜(II)积累。FDX1将Cu(II)还原为毒性更强的Cu(I),DLAT进一步与Cu(I)结合诱导DLAT寡聚化造成不溶性DLAT增多，蛋白应激诱导肿瘤细胞死亡。本发明提出的CHA@ESCu原料价格低廉，制备工艺简单，抗肿瘤效果优异，为肿瘤治疗提供了新的治疗思路。

一种含牡丹籽油的脂质体、其制备方法及其组合物和应用

Resumen de: CN122911926A

本发明公开了一种含牡丹籽油的脂质体、其制备方法及其组合物和应用，属于纳米脂质体药物技术领域。本发明利用微流控法制备L‑PSO脂质体，随后利用逐层包被法将壳聚糖与果胶逐层包于脂质体形成CL‑PSO和PCL‑PSO，相比于纯脂质体，修饰后的脂质体，特别是PCL‑PSO具有更加优越的稳定性，缓释性与体内靶向性。牡丹籽油靶向脂质体与长双歧杆菌组合形成的合生元在改善体重、降低DAI评分、恢复结肠长度、抑制脾脏肿大、重建菌群多样性及修复肠道组织病理损伤等方面均表现出显著的协同优势，其效果优于任一单一成分，提示合生元策略在结肠炎干预中具有更好的应用潜力。

一种薄荷来源外泌体样纳米囊泡及其制备方法和应用

Resumen de: CN122917985A

本发明属于生物医药及免疫治疗技术领域，具体涉及一种薄荷（Mentha）来源外泌体样纳米囊泡（Mint‑ELNVs）及其制备方法和作为载体和佐剂负载肿瘤抗原的纳米疫苗的应用，及其在制备预防或治疗肿瘤（特别是胶质母细胞瘤）的药物中的应用。制备方法，以新鲜薄荷叶为原料洗涤榨汁后依次进行低速离心和高速离心，收集上清液过滤，滤液再经超速离心，收集沉淀纯化即获得高纯度、高产率薄荷来源外泌体样纳米囊泡（Mint‑ELNVs）。该Mint‑ELNVs可作为天然佐剂和靶向载体。本发明的Ag@Mint‑ELNVs能够被树突状细胞（DC）高效摄取，并通过激活MAPK信号通路、下调淋巴内皮细胞紧密连接蛋白（ZO‑1,Occludin,Claudin‑5）及激活CCR7‑CCL21趋化轴，显著促进DC细胞的成熟、迁移及淋巴结归巢，从而诱导强烈的抗原特异性免疫反应。

一种基于树突状细胞膜的纳米制剂及其制备方法及应用

Resumen de: CN122911925A

本发明涉及一种基于树突状细胞膜的纳米制剂，该基于树突状细胞膜的纳米制剂包括：赖氨酸‑锰复合纳米核心，以及淋巴结靶向仿生外壳，用于所述纳米制剂肿瘤引流淋巴结的靶向以及免疫细胞相互作用；所述核心由L‑赖氨酸或其可药用盐/衍生物与二价锰盐通过配位、自组装、离子作用、沉淀或其组合形成；所述淋巴结靶向仿生外壳为包覆在所述核心外表面的树突状细胞膜和/或树突状细胞膜囊泡和/或保留树突状细胞膜关键蛋白的膜衍生物，该制剂兼具营养底物递送与免疫激活功能，并具备肿瘤引流淋巴结靶向能力。

光响应型高分子铜离子载体

Resumen de: CN122912117A

本发明涉及生物医用高分子材料及肿瘤治疗技术领域，尤其是涉及一种光响应型高分子铜离子载体。所述高分子铜离子载体为由卟啉‑铜配位高分子自组装形成的纳米颗粒；所述卟啉‑铜配位高分子包括高分子骨架、与所述高分子骨架共价连接的卟啉功能单元以及Cu2+；所述高分子骨架包括聚乙二醇链段以及具有卟啉连接位点的功能化链段；所述卟啉功能单元具有卟啉大环结构，且所述卟啉大环外围具有两个含羧基侧链；所述Cu2+与所述卟啉功能单元的卟啉大环中的氮原子配位。本发明提高了铜离子向肿瘤细胞内的递送效率，并结合光动力作用与铜死亡效应，增强肿瘤细胞杀伤能力。

一种尼达尼布-HSA-PEG纳米制剂的制备方法

Resumen de: CN122911923A

本发明公开一种尼达尼布‑HSA‑PEG纳米制剂的制备方法，包括以下步骤：称取尼达尼布溶于二甲基亚砜（DMSO）中得到尼达尼布‑DMSO溶液，另取人血清白蛋白（HSA）和聚乙二醇（PEG）溶于去离子水中，搅拌至完全溶解得到HSA‑PEG水溶液；在冰浴和超声条件下，将尼达尼布‑DMSO溶液以0.2‑0.8ml/min的速度缓慢滴加到HSA‑PEG水溶液中，继续室温搅拌2‑3h得到混合液；将混合液装入透析袋中透析除去游离药物和DMSO得到尼达尼布‑HSA‑PEG纳米制剂。本方法制备的尼达尼布‑HSA‑PEG纳米制剂及其在CNV治疗药物中的应用能够实现效果最优化。

薬物送達のためのペプチドナノスポンジ

Resumen de: WO2025076082A1

The present disclosure describes peptide nanosponges comprising a plurality of self-assembled peptide building blocks. The plurality of self-assembled peptide building blocks comprises a first peptide building block comprising: a branched polymeric core comprising at least three arms; a first block co-peptide covalently linked to one of said arms, wherein said first block co-peptide comprises a first peptide block and a second peptide block which is different from the first peptide block; a lipid-based capping moiety covalently attached to the first block co-peptide; and a therapeutically active compound covalently attached via a cleavable linkage to the first block co-peptide. Advantageously, the block co-peptide is covalently attached to the core such that it is resistant to enzymatic cleavage from the core.

併用療法

Resumen de: WO2025072649A1

A method for treating, inhibiting, or ameliorating cancer, such as KRAS-mutant cancer, including administering a GST-p inhibitor and either a KRAS inhibitor or a chemotherapy drug in therapeutically effective amounts to a subject suffering from the cancer in need thereof.

核酸治療剤の肺標的送達のための脂質複合体ナノ粒子

Resumen de: WO2025067389A1

A drug delivery system composing nanoparticles, in particular lipid nanoparticles ( LNPs ), and messenger RNA ( mRNA ), as well as methods for lung-targeted delivery of the nanoparticles.

一种抑制CREPT基因的siRNA及其的应用

Resumen de: WO2026209045A1

An siRNA for inhibiting a CREPT gene and use thereof. The siRNA comprises a sense strand and/or an antisense strand, and the sequence thereof is a sequence comprising any one of SEQ ID NOs. 1-194 and SEQ ID NOs. 243-368 and also comprises a sequence resulting from modification on the basis of these sequences. The use thereof comprises use as an expression vector, a host cell, a drug, etc. These sequences, drugs, etc., have significant effects in the treatment of liver diseases and liver lesions, such as the treatment of liver cancer, liver fibrosis, fatty liver, and other related diseases.

负载氧化铁纳米颗粒的间充质干细胞及其用途

Resumen de: WO2025184767A1

A composition that includes a stem cell and a coated iron oxide nanoparticle. The coated iron oxide nanoparticle, being present in the cytoplasm of the stem cell, contains a superparamagnetic iron oxide core that is coated with one or more biocompatible polymers, each of which has a polyethylene glycol group, a silane group, and a linker covalently linking the polyethylene glycol group and the silane group. Also provided is a method for treating an inflammatory disorder in which stem cells are cultured in the presence of coated iron oxide nanoparticles and the cultured stem cells are administered to a subject suffering from an inflammatory disorder. Further disclosed is a method for tracking stem cells in vivo by labeling stem cells with coated iron oxide nanoparticles, administering the labeled stem cell to an individual, and obtaining one or more T2 weighted magnetic resonance images of the individual to track the stem cells.

炎性肺部疾病的治疗

Resumen de: WO2025181030A1

The invention refers to therapeutical combinations or compositions comprising at least two miRNAs selected from the group consisting of miR-297, miR-93, and miRlet-7b, and their use in preventing and/or treating inflammatory lung diseases such as acute respiratory distress syndrome.

用于通过羟基酸氧化酶1的基因编辑治疗原发性高草酸尿症的方法

Resumen de: WO2025147604A1

A composition for genetic editing of a hydroxyacid oxidase 1 (HAO1) gene, comprising: (a) a messenger RNA (mRNA) encoding a Cas12i2 polypeptide, (b) a guide RNA (gRNA) targeting the HAO1 gene; and (c) lipid excipients, which optionally form lipid nanoparticles. Also provided herein are methods for genetic modification of the HAO1 gene in host cells with the composition provided herein.

一种坦布苏病毒EDIII自组装纳米颗粒及其制备方法和应用

Resumen de: CN122912108A

本发明中公开了一种坦布苏病毒EDIII自组装纳米颗粒及其制备方法和应用。本发明通过“分子胶水”SpyCatcher/SpyTag实现鸭坦布苏病毒EDIII与Ferritin NP的高效偶联，制得EDIII‑Ferritin NP。EDIII‑Ferritin NP免疫雏鸭后能激发强大的特异性体液免疫反应和细胞免疫反应，提供了更强的免疫保护效力，可有效减轻病毒感染后造成的组织损伤并强效抑制雏鸭体内病毒的复制，且其生产工艺简单、易操作，偶联产物稳定。因此，本发明制备的EDIII‑Ferritin NP可用于坦布苏病毒活疫苗的制备中，并实现工业化生产应用。

PH-RESPONSIVE BLOCK COPOLYMER NANOPARTICLE, PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: WO2026214081A1

Provided are a pH-responsive block copolymer nanoparticle, a preparation method therefor and the use thereof. The pH-responsive block copolymer nanoparticle is formed by connecting poly(N,N-dimethylaminoethyl methacrylate) and poly(2-(diisopropylamino)ethyl methacrylate) via a covalent bond. On the basis of a polymerization-induced self-assembly method, a pH-responsive nanoparticle with a controllable morphology and size is prepared under high solid content conditions by means of regulating the molecular composition of the block copolymer and the ratio of mixed polar solvents in the external environment. The pH-responsive block copolymer nanoparticles are used for preparing a biomedical drug delivery system.

METHOD OF TREATING CANCER CELLS USING F-BLOCK ELEMENT-SUBSTITUTED ZINC OXIDE NANOPARTICLES

Resumen de: US20260315525A1

0000 A method of treating cancer cells includes contacting cancer cells with ternary metal oxide nanoparticles to induce cell death of the cancer cells. The ternary metal oxide nanoparticles include a zinc oxide matrix doped with terbium and erbium. The terbium is present in an amount of 0.5 to 10 atomic percent (at. %), and the erbium is present in an amount of 0.5 to 10 at. %. Atomic percent is based on the total atom count of the zinc, terbium, and erbium. The erbium replaces zinc within the zinc oxide matrix. The ternary metal oxide nanoparticles have an average particle size of 22 to 32 nm.

CHITOSAN-BASED NANOCAPSULE SYSTEM FOR USE IN THE PROPHYLACTIC TREATMENT OF AN INFECTION CAUSED BY AN ENVELOPED VIRUS

Resumen de: US20260315405A1

Chitosan-based nanocapsule system for use in the prophylactic and/or therapeutic treatment of an infection caused by an enveloped virus. The present disclosure refers to the medical field. Particularly, it refers to a chitosan-based nanocapsule system for use in the prophylactic treatment of an infection caused by a respiratory pathogen, preferably an enveloped respiratory virus, wherein the nanocapsule system is administered intranasally.

COMPOSITIONS AND METHODS FOR CAR-T CELL THERAPY

Resumen de: US20260315537A1

0000 The present disclosure includes compositions and methods of treating cancerous growth. For example, methods of the present disclosure may include administering a first nanoparticle composition to a subject having the cancerous growth, administering a second nanoparticle composition to the subject having the cancerous growth, and/or administering CAR-T cells to the subject having the cancerous growth. The first nanoparticle composition, the second nanoparticle composition, or both, may include tumor necrosis factor alpha and/or interferon gamma.

METHODS AND COMPOSITIONS FOR DISCRETE SELF-ASSEMBLED PEPTIDE NANOSTRUCTURES

Nº publicación: WO2026217473A2 15/10/2026

Solicitante:

NANONEUROSCIENCES INC [US]
NANONEUROSCIENCES, INC

Resumen de: WO2026217473A2

Provided herein are nanostructures comprising a lipophilic component comprising a peptide segment coupled to a hydrophobic segment, an amphiphilic small molecule (ASM), and a metal cation. Also provided herein are compositions comprising the nanostructures, methods of preparation, and methods of administration.